{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:23:27Z","timestamp":1794626607458,"version":"4.9.1"},"reference-count":30,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2017,3,21]]},"DOI":"10.3233\/jad-160216","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T07:16:51Z","timestamp":1488784611000},"page":"557-573","source":"Crossref","is-referenced-by-count":66,"title":["Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer\u2019s Disease Patients"],"prefix":"10.1177","volume":"57","author":[{"given":"Nzeera","family":"Ketter","sequence":"first","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Robert","family":"Brashear","sequence":"additional","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bogert","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, LLC, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Di","sequence":"additional","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Miaux","sequence":"additional","affiliation":[{"name":"BioClinica Inc. (formerly Synarc), Newtown, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Gass","sequence":"additional","affiliation":[{"name":"BioClinica Inc. (formerly Synarc), Newtown, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk D.","family":"Purcell","sequence":"additional","affiliation":[{"name":"BioClinica Inc. (formerly Synarc), Newtown, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"Department of Radiology, VU University Medical Center, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Michael","family":"Arrighi","sequence":"additional","affiliation":[{"name":"Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-160216_ref1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer\u2019s amyloid beta-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.3233\/JAD-160216_ref2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.3233\/JAD-160216_ref3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2011.01.002","article-title":"Anti-abeta therapeutics in Alzheimer\u2019s disease: The need for a paradigm shift","volume":"69","author":"Golde","year":"2011","journal-title":"Neuron"},{"key":"10.3233\/JAD-160216_ref4","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"key":"10.3233\/JAD-160216_ref5","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/srep01302","article-title":"Bapineuzumab captures the N-terminus of the Alzheimer\u2019s disease amyloid-beta peptide in a helical conformation","volume":"3","author":"Miles","year":"2013","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-160216_ref6","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3174\/ajnr.A3500","article-title":"MR imaging features of amyloid-related imaging abnormalities","volume":"34","author":"Barakos","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.3233\/JAD-160216_ref7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: A retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-160216_ref8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-160216_ref9","first-page":"106","article-title":"Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer\u2019s disease treated with bapineuzumab: A historical, prospective secondary analysis","volume":"87","author":"Arrighi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-160216_ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3988\/jcn.2011.7.1.1","article-title":"Cerebral amyloid angiopathy: A systematic review","volume":"7","author":"Biffi","year":"2011","journal-title":"J Clin Neurol"},{"key":"10.3233\/JAD-160216_ref11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1212\/WNL.0b013e318221ad36","article-title":"Cerebral microhemorrhage and brain beta-amyloid in aging and Alzheimer disease","volume":"77","author":"Yates","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-160216_ref12","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/s00415-003-0245-7","article-title":"Cerebral microbleeds in Alzheimer\u2019s disease","volume":"250","author":"Hanyu","year":"2003","journal-title":"J Neurol"},{"key":"10.3233\/JAD-160216_ref13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jalz.2011.05.2353","article-title":"Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer\u2019s disease study cohorts from phase 3 trials of semagacestat and solanezumab","volume":"7","author":"Carlson","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-160216_ref14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","article-title":"A single ascending dose study of bapineuzumab in patients with Alzheimer disease","volume":"24","author":"Black","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-160216_ref15","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JAD-160216_ref16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-160216_ref17","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3174\/ajnr.A3475","article-title":"An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion","volume":"34","author":"Barkhof","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.3233\/JAD-160216_ref18","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/01.STR.32.6.1318","article-title":"A new rating scale for age-related white matter changes applicable to MRI and CT","volume":"32","author":"Wahlund","year":"2001","journal-title":"Stroke"},{"key":"10.3233\/JAD-160216_ref19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2466\/pr0.1966.19.1.3","article-title":"The intraclass correlation coefficient as a measure of reliability","volume":"19","author":"Bartko","year":"1966","journal-title":"Psychol Rep"},{"key":"10.3233\/JAD-160216_ref20","first-page":"649","article-title":"Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period","volume":"4","author":"Hankinson","year":"1995","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.3233\/JAD-160216_ref21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2004.09.003","article-title":"MRI and CT in the diagnosis of vascular dementia","volume":"226","author":"van Straaten","year":"2004","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-160216_ref22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-160216_ref23","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.jalz.2012.11.010","article-title":"Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: Implications for amyloid-related imaging abnormalities","volume":"9","author":"Zago","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-160216_ref24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-160216_ref25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-160216_ref26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1161\/STROKEAHA.108.526996","article-title":"improving interrater agreement about brain microbleeds: Development of the Brain Observer MicroBleed Scale (BOMBS)","volume":"40","author":"Cordonnier","year":"2009","journal-title":"Stroke"},{"key":"10.3233\/JAD-160216_ref27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0896-6273(93)90070-8","article-title":"Apolipoprotein E in sporadic Alzheimer\u2019s disease: Allelic variation and receptor interactions","volume":"11","author":"Rebeck","year":"1993","journal-title":"Neuron"},{"key":"10.3233\/JAD-160216_ref28","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","article-title":"Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JAD-160216_ref29","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bbadis.2010.05.004","article-title":"Murine models of Alzheimer\u2019s disease and their use in developing immunotherapies","volume":"1802","author":"Wisniewski","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-160216_ref30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000334763","article-title":"Clearance of amyloid-beta protein deposits in transgenic mice following focal cerebral ischemia","volume":"10","author":"Van Nostrand","year":"2012","journal-title":"Neurodegener Dis"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-160216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:03:18Z","timestamp":1777370598000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-160216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":30,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-160216","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,21]]}}}